Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicopass 1.5 mg lozenge for smoking urges in moderate smokers
2023-506787-13-00Phase 3Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nicotine dependence comparing Nicopass 1.5 mg nicotine lozenge with Placebo lozenge (2 arms). Primary endpoint: Change from baseline in QSU-brief Total score at 30 minutes. Started Feb 2024; status: completed.
02
Drugs
Nicopass
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2023-506787-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506787-13-00.